Vylor Inc.: The Seed Machine That Outgrew DuPont

The Central Questions of the Story

1. The Fraudulent Conveyance Trap: Did Corteva engineer a clean break that freed the Pioneer germplasm, or could the multistate PFAS litigation in South Carolina reach across the new corporate boundary and pull Vylor's balance sheet into legacy chemical liabilities?
2. The Royalty Neutrality Pivot: Can Vylor go from paying other companies for biotech traits to earning more from licensing its own, or will trait expirations in 2031–2032 and swings in input costs squeeze its margins first?
3. The Seasonal Debt Squeeze: Will a debt load of roughly $5.7 billion, more than half of it short-term, limit a business that burns about $2.5 billion of operating cash every spring before harvest money comes in?
4. The Pricing Power Limit: Can Vylor keep raising price and mix by about 3% a year when crop prices sag, farmer credit losses rise and global seed volumes stay flat?

---

↑ Back to Top

I. Prologue: The Midnight Remand in Charleston (0:00–0:15)

On the last day of September 2026, the most valuable seed company in the world was technically still a line item inside Corteva, and a federal appeals court had just put its independence back in doubt.

Two weeks earlier, on September 14, the State of California had walked into the sprawling firefighting-foam litigation consolidated in the District of South Carolina, the AFFF multidistrict litigation where thousands of PFAS "forever chemical" claims against the old DuPont family of companies are being fought, and asked a federal judge to stop Corteva's planned separation.¹ California did not come alone. It brought 18 other states, the District of Columbia, Puerto Rico and nine political subdivisions.¹ The theory came from an old corner of commercial law, the Uniform Voidable Transactions Act, which lets creditors undo transfers that strip a debtor of assets it will need to pay what it owes. The states argued that moving the seed business out of Corteva would wall off the crown jewel and leave the remaining chemical company, the entity carrying legacy DuPont environmental exposure, undercapitalized.¹¹²

The district court initially turned the request away on procedural grounds. Then, on September 30, the U.S. Court of Appeals for the Fourth Circuit summarily reversed that procedural denial and sent the matter back down.²¹³ For a few hours, a spin-off that had been planned for almost a year, with notes already sold, ratings already assigned and a record date already passed, hung on whether a trial judge would grant an injunction on remand.

The judge did not. On remand, the district court denied the injunction the same day.²⁴ Corteva's merger agreement-style closing conditions included the absence of legal restraints, and the board, having watched the remand play out, waived that condition and pushed the button.² On October 1, 2026, Corteva distributed one share of Vylor for each Corteva share held at the September 24 record date, about 667.2 million shares in all, and Vylor began trading on the New York Stock Exchange under the ticker VYLR.³⁵

What the market received that morning was the old Pioneer Hi-Bred, Henry A. Wallace's hybrid-corn company, now carrying a new name, a Johnston, Iowa headquarters and a balance sheet that had been rebuilt in the weeks before the spin.¹³ Just before separation, the seed company borrowed and sent roughly $3.08 billion of cash up to its parent to retire parent commercial paper.¹ That is the number the 19 states care about most. In fraudulent-transfer law, a large cash payment to a parent on the way out the door is exactly the kind of thing a court can be asked to claw back.

Why this is an Acquired story

Most corporate spin-offs are bookkeeping. This one is the end of a 27-year experiment. DuPont bought Pioneer in 1999 believing chemistry and genetics belonged under one roof.¹⁴ Dow and DuPont then merged and split, and Corteva was born in 2019 on the promise that seeds and crop protection would be worth more together.¹⁵ In November 2025, Corteva's own board decided the opposite and announced it would separate the two.⁶ And in a twist that says everything about where the value sits, it was the seed business, not the chemicals, that the accountants treated as the continuing company.¹

The verdict, and the roadmap

Vylor completed its spin-off, but its corporate boundary is still contested. Corteva obtained solvency opinions from an independent appraisal firm, and the separation agreement assigns historical PFAS liabilities of the old DuPont operating company to New Corteva rather than Vylor.¹ Those are real defenses. But the injunction denial decided only that the deal could close, not whether the transfer was fair, and the substantive fraudulent-conveyance claims remain live.¹²

The rest of this story follows the money from the beginning: how hybrid corn created a kind of biological copy protection, why a chemical conglomerate spent decades struggling to run a seed company, how the 2026 separation was structured and who paid for it, what the seed engine looks like inside, the fight to stop paying rivals for traits, the violent seasonality of the cash flow, the incentives of the people now running it, and finally whether the moat is as wide as the price implies. It starts in Des Moines, a century ago, with a man who would become vice president of the United States.

---

↑ Back to Top

II. The Wallace Legacy: Inventing Commercial Hybrid Seed (0:15–0:35)

In 1926, Henry A. Wallace was an Iowa farm editor with a scientist's habits and a stubborn streak. His family ran Wallaces' Farmer, his father would serve as Secretary of Agriculture, and Henry himself would later hold the same job before becoming Franklin Roosevelt's vice president. That year he and a group of backers set up the Hi-Bred Corn Company in Des Moines to sell hybrid seed corn, the business that later became Pioneer Hi-Bred.¹⁴

Wallace's insight was partly biological and partly commercial, and the commercial part is the one investors should linger on.

The science of hybrid vigor

Corn breeders had known for years that if you inbreed a corn line, forcing it to pollinate itself over generations, it gets weaker and more uniform. Cross two of those weak, uniform inbred parents, though, and the first-generation offspring can be dramatically stronger than either parent. Biologists call this heterosis, or hybrid vigor. The plants are taller, more uniform and higher-yielding.

The catch is the second generation. If a farmer saves the grain from a hybrid field and plants it the next spring, the genetic shuffle scatters the traits. The field comes up uneven and the yield falls sharply. The vigor does not breed true.

Think of it like a vintage that only exists for one year. The farmer can eat it, feed it to hogs or sell it, but cannot replant it and get the same thing. Every spring, the only way to get that first-generation performance again is to buy fresh seed from whoever owns the inbred parent lines.

Biological copy protection

That is why hybrid corn may be one of the oldest and most durable forms of recurring revenue in industry. Software companies spent decades building license keys and subscriptions to stop copying. Wallace's product enforced the rule by itself. Vylor's disclosures still describe the same dynamic: growers cannot save hybrid seed for replanting without suffering a yield loss, which turns the seed purchase into an annual decision rather than a one-time one.¹

A century later, corn still dominates the business. In 2025, corn seed brought in about $7.0 billion, or roughly 71% of the seed business's sales.¹ Soybeans, which are not hybrids in the same way and depend more on patented traits and licensing for protection, made up about 19%.¹ The asymmetry matters: the company's largest product line carries the natural lock, while the second-largest relies more on legal and contractual ones.

The farmer-dealer

Wallace's company did something else that turned out to be just as important. Rather than relying solely on feed stores and general farm retailers, Pioneer built a network of farmer-dealers, local growers who sold seed to their neighbors on commission. The person explaining why a particular hybrid would suit a field was often someone who farmed similar ground down the road.

That model survives today. Vylor sells its flagship Pioneer brand through an exclusive direct-to-grower sales agency network made up of thousands of independent representatives.¹ The neighbor-as-salesperson structure is hard to copy because it is not really a channel. It is a set of relationships, local trial data and trust built over generations.

The germplasm library

The third element is the least visible and probably the most valuable. Every year for a hundred years, Pioneer's breeders planted, measured and selected. The result is a germplasm library: a catalog of parent lines adapted to specific soils, day lengths, disease pressures and climates. A hybrid that wins in central Illinois may lose in Minnesota. Knowing which genetics win where, with yield data from countless plots, is the accumulated output of a century of repeated experiments.

You cannot buy that history quickly. A newcomer can license traits, hire breeders and buy land for trials, but cannot buy a century of breeding cycles. Each cycle takes at least a growing season. That time constraint is the root of the moat argued in full later in this story.

A culture of agronomists

Pioneer also grew an insular, Midwestern culture centered on agronomy and the farmer relationship, and it was skeptical of chemical companies that saw seed as a delivery vehicle for their own products.¹⁴ That attitude would matter when the chemical company arrived. Its next owner thought in a very different time scale: big plants, big capital budgets and molecules with patents that run out.

---

↑ Back to Top

III. The Conglomerate Trap: DuPont, Dow, and the 27-Year Detour (0:35–1:00)

In 1999, E.I. du Pont de Nemours & Co., the Wilmington, Delaware chemical giant that had given the world nylon and Teflon, agreed to buy the roughly 80% of Pioneer Hi-Bred it did not already own for about $7.7 billion.¹⁴ DuPont's leadership described a future in "life sciences," where synthetic chemistry, biotechnology and seeds would reinforce one another. Pioneer's genetics would carry DuPont's traits and pesticides onto millions of acres.

It was a reasonable-sounding thesis. It was also, in hindsight, the beginning of a long detour.

Wilmington versus Johnston

The cultural problem was a problem of time. Chemical businesses run on large, lumpy decisions: build a plant, commission it, run it for decades, and accept that a new molecule's patent clock is ticking. Seed businesses run on steady, compounding work: plant the trial plots every year, keep spending on breeding through good harvests and bad, and wait for genetics that take most of a decade to reach market.

Today, Vylor spends about 10% of sales on research and development, a level management says it intends to hold as a standalone company.¹ That is the kind of constant reinvestment a breeding program needs. In a conglomerate, every one of those dollars competes with capital requests from businesses with different cycles and different priorities.

The Monsanto trait coup

While DuPont's broader portfolio absorbed management attention, Monsanto did something that reshaped the industry. It commercialized herbicide-tolerant Roundup Ready crops and insect-resistant Bt traits and licensed them widely, including to rivals. Pioneer had the better germplasm in many markets, but much of the biotech engine inside its seed came from Monsanto.

Here is the key analogy for the rest of the story. Germplasm is the car: the chassis, engine tuning and handling, adapted to local roads. Traits are added equipment, like a specific safety system that comes from another manufacturer. Farmers want both. When the best equipment belongs to your rival, you pay the rival a fee on every car you sell.

DuPont's own attempt to build an alternative herbicide-tolerance platform, Optimum GAT, did not become the independent trait franchise the company had hoped for, and Pioneer remained a heavy licensee of Monsanto technology for many years. The legal fights over those licenses, including a major patent and antitrust battle with Monsanto in the late 2000s and early 2010s, made the dependency public.

The cost of that dependency shows up in Vylor's own accounts as recently as 2025: the seed business recorded a $610 million charge to resolve its remaining cross-license and trait disputes with Bayer CropScience, which absorbed Monsanto in 2018.¹¹¹ More on that in Section VI. For now, the point is that the bill for two decades of trait dependency was still being paid on the eve of independence.

The activist storm

By 2015, DuPont's conglomerate structure had attracted Nelson Peltz's Trian Fund Management, which argued the company should break apart. DuPont won the proxy fight that spring, but the pressure did not go away. Months later, DuPont and The Dow Chemical Company announced a merger of equals, with a plan to combine and then split into three focused companies.¹⁵ The merged DowDuPont came together in 2017, at a combined value of roughly $130 billion.¹⁵

Corteva's bundle

In 2019, DowDuPont completed its split into Dow (materials), DuPont (specialty products) and Corteva (agriculture).¹⁵ Corteva combined Pioneer seed with Dow and DuPont crop protection chemistry, and its story to investors was integration: one company selling the seed and the chemicals to protect it.

The weakness of that story can be stated in one sentence. Farmers buy crop protection on price, and they buy seed on yield. Off-patent herbicides and insecticides are available from generic manufacturers, and farmers shop across them. A proven hybrid on a farmer's own ground is something they rarely change lightly. A bundle that ties a high-loyalty product to a price-shopped one gives the buyer every reason to unbundle it in practice.

Myth versus reality

Myth: DuPont's ownership destroyed Pioneer. Reality: the seed business kept growing; it was the largest part of Corteva's value by the time of separation, large enough to be treated as the accounting acquirer in the spin.¹ What the conglomerate years cost was not the germplasm. They cost trait independence and, through it, margin paid to a rival, plus a decades-long legal fight that ended with a large check.

So the next question is simple. If the bundle never worked, why did it take until 2025 to undo, and who paid for the divorce?

---

↑ Back to Top

IV. "Project Unbundle": The 2026 Reverse Spin-Off (1:00–1:20)

On November 13, 2025, a new Delaware corporation came into existence with the least romantic name in agricultural history: Seed External Spinco Inc.¹ Days later, Corteva told investors it would separate its seed and crop protection businesses into two public companies.⁶ In April 2026, the shell was renamed Vylor Inc.¹

The interesting part was not the decision to separate. It was the direction.

Why "reverse"

In a normal spin-off, the parent keeps the main business and hands shareholders a smaller one. Here, Corteva distributed the seed business, yet under the accounting rule for spin-offs (ASC 505-60), Vylor is treated as the continuing entity. Corteva's historical consolidated statements become Vylor's predecessor statements, and the crop protection business is the piece shown as separated.¹

Accountants call this a reverse spin-off, and they reach for it when the business being distributed is the more significant one. Put plainly: the accounting says the seed company is the real Corteva. That conclusion is itself the strongest evidence for the thesis that Pioneer was always the economic engine and the conglomerate was the passenger.

The distribution itself was clean: one Vylor share for each Corteva share, about 667.2 million shares, intended to be tax-free to shareholders.¹⁵ Corteva kept no equity stake.¹

Who paid for the divorce

Here the story turns from elegant to pointed. Before the distribution, Vylor took on debt and used about $3.08 billion of it to pay a cash dividend up to the parent, which used the cash to repay commercial paper.¹

Walk through what that does. The seed company leaves the family with a loan that was taken out to repay the family's borrowings. On its first day as an independent company, Vylor carried about $5.67 billion of total borrowings against about $1.1 billion of cash.¹ The debt came in three main pieces:

• $1.1 billion of new senior notes sold on August 31, 2026, split evenly between a 5.125% tranche due 2031 and a 5.625% tranche due 2036.¹
• About $1.4 billion of notes issued in exchange for older notes of EIDP, the legacy DuPont operating company, due 2030, 2032 and 2033.¹
• About $3.1 billion of short-term borrowings, drawn on a $3.5 billion bridge facility from BBVA's New York branch, to be replaced by a five-year revolver, a 364-day revolver and a $3.5 billion commercial paper program.¹

From a parent's perspective, this is ordinary spin-off engineering: send leverage to the business with the steadiest cash flow. From a creditor-of-the-parent's perspective, it looks like the seed business paid the parent to leave. That framing is exactly the one California and the other states brought to court.¹¹²

There is also a governing ratio for liabilities nobody can assign cleanly. General corporate liabilities that predate the spin are shared by an "Applicable Percentage": 62% to Vylor and 38% to New Corteva.¹ That split roughly tracks relative value, but it means Vylor is not a stranger to its parent's past. It has contractually accepted most of the shared, unallocated history, while legacy PFAS sits specifically with New Corteva.

The commercial tether

Separation does not mean independence in operations. Vylor and New Corteva signed a separation agreement, a transition services agreement, a tax matters agreement, an employee matters agreement and an intellectual property cross-license.¹ The seed company also buys seed treatment chemistry from its former sibling. In the first half of 2026, those purchases reached $121 million, up from $102 million a year earlier.¹ These are small relative to sales, but they matter for two reasons: they are a recurring related-party flow worth watching for pricing, and they show that the "bundle" survives as a supplier contract even after it died as a corporate structure.

The cash trail before separation tells the same story about who funded whom. Net transfers from the seed business up to the parent rose from about $0.6 billion in 2023 to about $2.0 billion in 2025.¹ The seed engine had been sending increasing amounts of cash upstream for years; the pre-spin dividend was the final, largest installment.

Why management chose the seed side

The executive team followed the seed business. Corteva's CEO, Charles V. "Chuck" Magro, and CFO David P. Johnson took the same roles at Vylor.¹ Managers rarely leave the bigger, better business behind, and the choice is a strong signal about where they see value. It also means the people who designed the leveraged structure are now the people who must live inside it.

The structure is set. The next question is whether the engine underneath can carry it.

---

↑ Back to Top

V. Inside the Seed Engine: Germplasm, Traits, and the Route-to-Market (1:20–1:45)

Picture a farmhouse kitchen in Iowa in November. Harvest is done. The yield monitor data from the combine has been downloaded, and the farmer knows, acre by acre, how each hybrid performed. Across the table sits a Pioneer sales representative, often a farmer too, with trial results from plots in the same county. Together they choose next year's hybrids, populations and seed treatments for an April planting that is five months away. A deposit may change hands.

That kitchen-table meeting is the unit of Vylor's business. Everything else, from biotech labs to bond indentures, depends on what happens there.

The scale and the shape

In 2025, the seed business recorded about $9.9 billion in net sales.¹ Over the seven years from 2018, sales grew at about 3.4% a year, from roughly $7.8 billion.¹ That is steady, not spectacular, and it is the base rate every growth story should be measured against. It is roughly the pace of agricultural output growth plus modest pricing.

Gross margin runs around 52%, the kind of number associated with branded consumer goods or software rather than farm inputs.¹ The reason is the same as Wallace's: the customer pays for the genetic information, not the kernel.

About 63% of 2025 sales came from North America; Latin America, Europe/Middle East/Africa and Asia Pacific supplied the rest, at roughly $1.6 billion, $1.6 billion and $0.45 billion respectively.¹ The concentration in North American corn means the company's fortunes rise and fall with one farm economy more than its global footprint suggests.

Where growth actually comes from

Here is the clue that matters most for the long-term story. In the first half of 2026, sales grew about 4%, driven by a 3% gain in price and mix and a 1% currency benefit. Volume was flat.¹ In 2025, volume grew about 2%.¹

The conclusion is straightforward: Vylor's growth is primarily a pricing story. The company is selling roughly the same number of units into mature crop belts and charging more for better genetics and traits. That is evidence of pricing power, but it is also evidence that the market is largely saturated. Over long periods, a business that grows almost entirely through price depends on farmers continuing to believe each new hybrid earns its premium. Section IX returns to how well that belief holds when crop prices fall.

Two brands, two channels

Vylor runs a deliberately split distribution system.¹

• Pioneer, the flagship, goes direct through the exclusive sales agency network. The representatives work on commission and own the relationship.
• Brevant and regional brands such as Dairyland Seed, Hoegemeyer and Nutech go through agricultural retailers, the same dealers that sell fertilizer and chemicals.

Why both? Because some growers will never buy direct, and some retailers want a premium genetics line on their shelf. The two-channel approach lets Vylor reach growers in both camps without forcing Pioneer's direct model to compete on retail price. No single customer accounts for 10% of sales.¹

The asset-light factory

Vylor does not grow most of its own seed. It contracts thousands of independent growers to produce parent and commercial seed under seasonal agreements, usually near the markets where the seed will be sold.¹ Vylor supplies the parent genetics and protocols; the contract grower supplies land, labor and equipment. The company then cleans, conditions, treats and bags the seed in its own facilities.

This is a clever structure. It keeps farmland off the balance sheet and turns land into a variable cost. Capital spending ran at about 3.5% of sales in 2025, modest for a business with this many physical steps.¹ The company also uses supplier finance programs, where a bank pays suppliers early and Vylor pays the bank later; balances were small, about $53 million at the end of 2025.¹

The working-capital reality

The trade-off for that asset-light design is time. Seed must be produced a season or more before it is sold, processed in the winter, delivered in the spring and often paid for after harvest. Vylor is effectively financing a year-long biological supply chain. The company employs about 12,300 people to run it.¹

That is the hidden cost of the 52% gross margin. The income statement looks like a branded franchise; the balance sheet behaves like a commodity merchant with a very long inventory cycle. Section VII follows that cash. First, the other half of the product: the traits.

---

↑ Back to Top

VI. The War for Trait Royalty Neutrality (1:45–2:05)

In January 2026, Corteva's seed leadership signed a settlement with Bayer CropScience that ended years of litigation over trait licenses, including disputes tied to the AAD-1 herbicide-tolerance trait and Enlist E3 soybeans.¹¹¹ The price was $610 million, recorded as a charge in the seed business's 2025 accounts.¹ By the end of the second quarter of 2026, $546 million had been paid; the remainder was due in September.¹

For a business that earned about $575 million of net income in 2025, the settlement was roughly a full year of profit.¹ It is the clearest number in the file for what trait dependency has cost.

The margin stack

Recall the car analogy: germplasm is the car, traits are the specialized equipment. When a farmer pays for a bag of Pioneer corn with stacked traits, part of the price rewards the germplasm and part rewards the traits. When the traits belong to a rival, a slice of that price leaves the building as a royalty.

Vylor's stated goal is "royalty neutrality": the point at which the royalties it collects from licensing its own technology to others match or exceed the royalties it pays to them.¹ It is pursuing that through its own trait families, including Enlist E3 soybeans, Optimum GLY, Vorceed Enlist corn and PowerCore, and a gene-editing patent estate it describes as the second-largest in agriculture worldwide.¹

What the evidence shows so far

The trend is real but modest. Management attributes about a $50 million reduction in royalty expense in 2025 to the shift toward its own traits.¹ Enlist E3 soybeans are the flagship success: a trait platform the company controls that has displaced licensed technology on a large share of acres. And the Bayer settlement removed the main legal cloud over that platform.

The historical falsification test cuts both ways. The company's own record includes a long stretch, roughly two decades, in which its earlier attempt at an independent trait platform, Optimum GAT, did not free it from licensing Monsanto technology. That history argues for caution about announcements that precede adoption. Enlist E3 is different in kind: it is commercial, at scale and in farmers' fields. What remains unproven is the net figure. The company does not separately disclose total out-licensing income against total royalty expense in the material here, so the claim of approaching neutrality rests on direction rather than a published balance.

The verdict: the history narrows the claim rather than rejecting it. Vylor has crossed into trait self-sufficiency on soybeans and is reducing its royalty bill. "Net out-licensor" is still a goal, not a fact.

CRISPR in plain English

Gene editing is the part of the pitch that sounds most like science fiction, so it deserves a plain explanation. Traditional biotech traits usually insert a gene from another organism, such as a bacterial gene that makes a plant toxic to certain insects. That process takes years of regulatory review. CRISPR-Cas works more like a word processor's find-and-replace: it lets breeders make precise edits to a plant's own DNA, for example to switch on disease resistance or adjust plant architecture.

In several major jurisdictions, simple edits that could have occurred through conventional breeding face lighter regulation than transgenic traits. If that holds, gene editing could compress the time and cost to bring new traits to market. Vylor's patent estate, a large share of it controlled jointly with academic institutions under licensing arrangements, could also generate fees from other companies using the tools.

A patent estate is not revenue, though. The company does not disclose meaningful gene-editing product revenue, and the history of agricultural biotech is full of promising techniques that took far longer to commercialize than expected. Gene editing is a real option with an unquantified payoff.

The 2031–2032 clock

Some of the core biotech corn and soybean traits Vylor relies on reach patent expiration in 2031 and 2032.¹ Expiry works both ways. Traits the company licenses from others may become cheaper. Its own traits may face generic copies, as Roundup Ready soybeans did after their patent expired. The net effect depends on which side of each expiring patent Vylor stands on, and the company does not publish that breakdown.

Management's plan is to refresh the stack with newer traits and gene-edited disease and drought tolerance. The scorecard to watch is whether the next generation reaches farmers before the current generation's protection fades. Spending about 10% of sales on R&D, roughly $1 billion in 2025, gives the company the budget to try.¹

The traits explain the margin. The next section explains why that margin does not turn into cash evenly across the year.

---

↑ Back to Top

VII. Forensic Balance Sheet: Seasonality, Factoring, and Cash Flow (2:05–2:25)

Spring 2026. Across the U.S. Corn Belt, planters roll. Seed trucks leave conditioning plants, and growers who paid deposits last fall take delivery. In Vylor's books, the deposits that sat as liabilities convert into revenue, and the sales that are not prepaid turn into receivables that will not be collected until after harvest. Treasury draws on short-term funding to bridge the gap.

The puzzle for this section: how can a business generate about $2.5 billion of operating cash in a year and burn about $2.5 billion in six months?

The two halves of the year

The full-year figure is real. In 2025, the seed business produced about $2.5 billion of operating cash flow against net income of about $575 million.¹ Cash ran far ahead of profit because of about $0.8 billion of depreciation and amortization, growth in customer prepayments, and the accrued but unpaid Bayer settlement, which reduced profit in 2025 but did not leave as cash until 2026.¹ That last item is important: a meaningful part of 2025's cash "surplus" was simply a bill paid late.

Now look at the first half of 2026. Operating cash flow was negative by about $2.5 billion, even though net income was about $1.5 billion.¹ Two seasonal swings did it: receivables built by about $2.1 billion, and deferred revenue, the farmer prepayments collected the previous autumn, unwound by about $2.9 billion as seed was delivered.¹ The outflow was also about $0.9 billion worse than in the first half of 2025, partly because the Bayer payments landed in this window.¹

The analysis in plain English: Vylor's customers finance it in the autumn and Vylor finances them in the spring. Prepayments act like an interest-free loan from farmers that Vylor must repay in seed. When the seed ships, that "loan" disappears from the balance sheet and the company needs other funding. A full-year cash conversion ratio of more than 200% of net income is true but uninformative about liquidity during planting season.

Receivables forensics

At the end of 2025, net receivables were about $1.85 billion, little changed from a year earlier.¹ Inside that number, about $104 million were trade notes, mostly from U.S. deferred-payment seed loan programs with terms of a year or less, essentially credit Vylor extends to farmers.¹

The clue worth highlighting is the allowance for credit losses. It rose from about $110 million to about $144 million during 2025, as new provisions jumped from about $25 million to about $64 million.¹ Write-offs barely moved, about $30 million.¹ So the company was not yet losing more money to bad debts; it was reserving for more trouble ahead. That pattern is consistent with tightening farm economics: lower crop prices and higher costs make some growers slower to pay.

Factoring is small. Vylor sold about $59 million of receivables to banks in 2025 and kept only about $4 million of recourse exposure.¹ It is not a material source of disguised financing.

Currency friction

About 37% of sales come from outside the U.S., and Latin American currencies have been a steady drain.¹ Net foreign exchange losses ran around $100 million to $120 million a year from 2023 through 2025.¹ The Argentine peso was the most dramatic piece: its 2023 devaluation alone cost about $119 million before tax.¹ The company hedges centrally in the U.S. with forward contracts to keep net monetary positions balanced, but hedging dampens swings rather than eliminating them.¹

Debt service and covenant headroom

The pro forma balance sheet carries about $4.6 billion of net debt.¹ Rating agencies put pro forma leverage at roughly 2.4x to 2.8x debt to EBITDA.¹ All three major agencies rated Vylor investment grade before the spin: Moody's at Baa1 for senior unsecured debt and Prime-2 for commercial paper, and S&P and Fitch at BBB+, with S&P's short-term rating at A-2.⁷⁸⁹¹⁰ The agencies cited market leadership and germplasm breadth as strengths and pointed to leverage, seasonal borrowing and farm-income cyclicality as constraints.¹

The single financial covenant in the revolving credit agreements caps total debt to total capitalization at 0.60; pro forma, Vylor sits at about 0.32.¹ That is wide headroom.

The verdict: the balance sheet is not fragile, but it is more stretched than a business with this seasonality would ideally carry. About $3.1 billion of the debt is short-term, and the peak spring borrowing need sits on top of that. Vylor will roll that short-term debt through commercial paper markets every year. In a calm market, that is routine for a Prime-2 issuer. In a stressed one, it is the moment when a company finds out how committed its backstop lines really are.

Which leads to the question of what the people managing this balance sheet are paid to do.

---

↑ Back to Top

VIII. Governance, Incentives, and the Ghost of DuPont (2:25–2:40)

In early 2026, the compensation committee faced an unusual problem: how do you set annual targets for a company that will exist in two forms during the same year? Its answer was to drop free cash flow from the short-term bonus formula. For 2026, annual incentives are tied 75% to operating EBITDA and 25% to operating EBITDA margin.¹ The committee pointed to the mid-year separation as the reason.¹

There is a defensible rationale. Free cash flow in a year containing a spin-off, a $3.08 billion dividend to the parent and the tail of the Bayer settlement would be hard to measure fairly. But the choice has a consequence. In the one year when the company has just added significant debt and has the most reason to show cash discipline, the bonus scorecard ignores cash entirely.

The CEO

Chuck Magro came to Corteva in 2021 from the fertilizer industry. He had run Agrium, the Canadian fertilizer and farm retail company, led its merger with PotashCorp to form Nutrien, and served as Nutrien's first CEO. That background matters. He has done large, complex combinations, and he has run a business with seasonal farm-retail working capital. He also oversaw the 2026 separation of the business he was hired to run as a combined company, which is either evidence of intellectual honesty or a sign that the original Corteva thesis did not survive contact with reality, and probably both.

In 2025, Magro's reported compensation was about $17.5 million: roughly $1.4 million in salary, about $11.7 million in stock and option awards, and about $4.0 million in annual cash incentive.¹ Total pay rose from about $13.2 million in 2023.¹ The disclosures also show about $184,000 of personal aircraft use.¹ CFO David Johnson received about $4.5 million.¹

Compare that to results. Seed net income moved from about $654 million in 2023 to about $575 million in 2025, depressed by the settlement charge.¹ CEO pay rose about a third in the same period. Some of that reflects Corteva's broader results, and the settlement is arguably a cleanup charge that management should not be punished for. But the comparison is the kind a skeptical investor will make.

Alignment through ownership

On ownership, the rules are strict. The CEO must hold stock worth six times base salary and executive vice presidents four times.¹ Directors and officers are barred from short sales, hedging, margin borrowing and pledging company shares.¹ Those are meaningful protections against the worst forms of misalignment.

The activist's questions

A skeptical long-term holder, or an activist, would press on three points:

1. Cash metrics. Will free cash flow or return on invested capital return to the incentive plan in 2027, now that the separation is complete?
2. Leverage target. What leverage does management aim to reach, by when, and does it come before buybacks?
3. The related-party tether. How are seed treatment purchases from New Corteva priced, and when do the transition services end?

None of these questions implies wrongdoing. They are the questions that determine whether the new company is managed for per-share value or for EBITDA scale. Vylor's board must be independent of New Corteva's, and the market will be watching whether it acts like it.

With the incentives on the table, it is time to ask whether the moat justifies the price.

---

↑ Back to Top

IX. Analysis: Moat Durability & The Bear vs. Bull Case (2:40–2:55)

On October 2, 2026, the second day of trading, the debate over Vylor came down to one tension. Is it a defensive, high-margin agricultural biotech franchise that deserves a premium, or a cyclical seed producer with slow volume growth and a lawsuit hanging over it?

What the price implies

At around $85 a share, a level early coverage used as a reference point, Vylor's equity would be worth about $57 billion and its enterprise value, including net debt, about $61 billion.¹ On a pro forma basis that is about six times 2025 sales and roughly 24x to 27x normalized operating EBITDA.¹

Translate that into expectations. A multiple in the mid-20s is usually reserved for businesses that combine durable pricing power with growth well above inflation. Vylor's long-run sales growth is about 3.4% a year.¹ So the price assumes one or more of the following: margins expand meaningfully, trait royalties swing from cost to income, gene editing produces new growth, or the market simply values the predictability of the franchise above its growth rate. It also prices Vylor well above diversified peer Bayer, which carries crop protection and litigation burdens, and closer to pure-play seed companies such as KWS Saat.¹

Hamilton Helmer's 7 Powers

Cornered Resource. The century-long germplasm library is the clearest power. It is the accumulated result of breeding cycles that cannot be accelerated by money alone. The gene-editing patent estate may become a second cornered resource; for now it is an option.

Switching Costs. For a farmer, seed is a small share of total cost but a large share of risk. Switching to an untested hybrid to save a few dollars an acre puts a year's yield on the line. That makes Pioneer customers sticky. The test of this power is price realization in bad years, and here the record is encouraging but bounded: price and mix kept rising about 3% in 2025–2026 while volume stalled.¹

Network-like economies. Every plot of yield data improves the company's ability to place the right hybrid on the right field, which helps the next grower nearby. This is a real data advantage, but it is not a network effect in the software sense: competitors run large trial networks too.

Scale economies, counter-positioning, brand, process power. Scale in R&D is meaningful: about $1 billion a year of spending is a barrier for smaller rivals.¹ Pioneer is a strong brand among growers. Counter-positioning and process power are weaker arguments here.

Porter's Five Forces

• Buyers: Individually weak; no customer reaches 10% of sales.¹ Collectively constrained by farm income, which is where the rising credit provisions show up.¹
• Suppliers: Moderate. Contract growers can plant something else if production contracts are not attractive, which forces Vylor to pay competitive rates. The company also buys seed treatments from New Corteva, a concentrated relationship.¹
• Substitutes: Very limited for row crops. Biologicals are complements, not replacements.
• New entrants: Very low threat. Replicating a breeding program and trial network takes decades.
• Rivalry: A concentrated oligopoly with Bayer and Syngenta, historically fought through traits and litigation. The $610 million settlement shows how expensive that rivalry can be.¹

Falsifying the moat

The strongest disconfirming evidence in Vylor's own record is volume. The business has not grown units much in mature markets, and the company's growth leans on price. Pricing power that rests on genetic gains is durable only as long as each new generation of hybrids delivers enough extra yield to justify its price. If crop prices fall far enough, farmers may trade down to cheaper hybrids or retail brands. The rising credit allowance is an early sign that farmer liquidity is tightening.¹

The verdict: the history narrows the moat claim rather than refuting it. Vylor has a wide moat around share and margin in its core corn markets. It does not have a moat around growth. The premium valuation needs both.

The bear case

• The courtroom. The fraudulent-transfer claims succeed on the merits, and a court orders money damages or a clawback tied to the $3.08 billion pre-spin dividend.¹²
• The farm cycle. Corn and soybean prices weaken further, pricing gains stall and farmer credit losses rise beyond reserves.
• The trait clock. Rivals design around Vylor's patents or next-generation traits arrive late, so 2031–2032 expirations hurt more than they help.
• The balance sheet. Seasonal borrowing and debt service absorb cash, delaying buybacks and dividend growth.

The bull case

• The courtroom. Claims are dismissed on the merits, removing the overhang.
• Traits. Enlist E3 and Vorceed adoption accelerates, and out-licensing turns royalties into a net income stream.
• Gene editing. Disease- and drought-tolerant hybrids earn premium pricing and lift growth above the historical rate.
• Deleveraging. Leverage falls from the mid-2s toward 1.5x, freeing cash for repurchases within a few years.

Three KPIs that settle it

1. Price/mix versus volume in seed sales. Latest reading: 3% price/mix, flat volume in the first half of 2026.¹ Direction: growth increasingly driven by price.
2. Net trait royalty balance. Latest reading: royalty expense down about $50 million in 2025; the net balance is not disclosed.¹ Direction: improving.
3. Peak short-term borrowing in the first half. Latest reading: about $3.1 billion of short-term debt at separation, before the spring peak.¹ Direction: the first standalone test comes in 2027.

---

↑ Back to Top

X. Playbook: Business & Investing Lessons (2:55–3:05)

Lesson 1: Biological intellectual property outlasts synthetic chemistry. In 1926, Henry Wallace sold a product that could not be copied by the people who bought it. A century later, DuPont's chemistry businesses had faced patent cliffs and environmental liability, while Pioneer's genetics remained the most valuable thing in the building.¹¹⁴ For founders, the lesson is to find protection that is built into the product, not only into the legal system. For investors, it is to ask what happens to a company's margins on the day its patents expire.

"A formula can go generic; a century of breeding cycles cannot."

Lesson 2: You cannot carve out the cash flow without carving out the seasonality. Vylor reported about $2.5 billion of operating cash in 2025 and then used about $2.5 billion in the first half of 2026.¹ Both numbers are true. The lesson for anyone analyzing a spin-off is to read the cash flow statement by quarter before reading the annual cash conversion. For a seed company, the balance sheet that matters is the one in May.

"On the annual report, seed is a cash cow. In May, it is a furnace burning commercial paper."

Lesson 3: A spin-off is not a shield until a court says so. Corteva had solvency opinions, contractual liability assignments and investment-grade ratings. It still needed an overnight board waiver to close, after 19 states took the separation to the Fourth Circuit.¹² The lesson for boards is that the fairness of the transfer, especially a large cash payment to the parent, becomes the evidence. For investors, the lesson is to price the time it takes for that question to be settled.

"A board can divide assets overnight; a court decides whether the line holds."

Lesson 4: The customer unbundles first. Corteva's thesis was that farmers would want seed and chemicals together. Farmers kept buying the chemicals where they were cheapest and the seed where it performed best. Six years after its founding, Corteva's board separated the two.⁶ The lesson for strategy is that a bundle survives only if both halves earn loyalty.

"When half a bundle is loyalty and half is a commodity, the customer splits the company long before the board does."

---

↑ Back to Top

XI. Epilogue & Outro (3:05–3:15)

Where Vylor stands tonight

On October 3, 2026, Vylor is three days old as a public company. It owns the most recognized name in North American corn seed, holds investment-grade ratings, carries more debt than it would have chosen on its own, and faces a fraudulent-transfer case that it did not create but cannot ignore.¹⁷¹⁰

Three moments will decide the next chapter.

The courtroom. The South Carolina district court will move from the injunction question to the merits of California's claims. A dismissal would remove the largest overhang and answer the first central question. An adverse ruling would turn the $3.08 billion pre-spin dividend from a historical footnote into a contested liability. A long, unresolved case is the most likely middle ground, and it would keep a discount on the shares for as long as it lasts.

The first 10-K. Vylor's first annual report as an independent company, covering 2026, will show whether volume grew or stayed flat, whether price/mix held around 3%, and whether management chooses to publish a net trait royalty figure. Each answers a central question directly: pricing power and royalty neutrality.

Spring 2027. The first independent planting season will test the commercial paper program and revolvers when the company needs them most. Peak short-term borrowing in the first half of 2027 will show how much room the leveraged structure really leaves.

The tension that remains is simple to state. Vylor's franchise is probably the strongest it has been in decades; its balance sheet and legal status are the least settled. The market is pricing the first; the next twelve months will test the second.

Outro

Back to Johnston, Iowa. A seed company that started in a modest Des Moines operation in 1926 spent 27 years inside a chemical empire, watched its parent merge with a rival and split into three, and finally stepped out on its own on a morning when its independence had been in doubt only hours before.

Chemists in Delaware spent decades trying to build the future of agriculture in the lab. The most durable value turned out to be in Iowa soil: a library of genetics that farmers must buy again every spring. Pioneer survived DuPont, outlasted Dow, and walked out of a South Carolina courtroom as Vylor. Now it has to prove it can carry the debt that came with the door.

References

1. Information Statement of Vylor Inc., Exhibit 99.1 to Form 8-K — SEC EDGAR, 2026-09-24 ↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩

2. Current Report on Form 8-K (Fourth Circuit California Remand & Legal Restraints Waiver) — SEC EDGAR, 2026-09-30 ↩↩↩↩↩↩

3. Current Report on Form 8-K (Completion of Separation & Corporate Formation) — SEC EDGAR, 2026-10-01 ↩↩

4. Current Report on Form 8-K (Separation Update & Court Injunction Denial) — SEC EDGAR, 2026-09-30 ↩

5. Current Report on Form 8-K (Distribution Press Release & Exchange Ratio) — SEC EDGAR, 2026-09-24 ↩↩

6. Corteva to Separate Seed and Crop Protection Businesses — Corteva Investor Relations, 2025-11-18 ↩↩↩

7. Moody's Assigns Baa1 Senior Unsecured Rating to Vylor Inc. — Moody's Ratings, 2026-08-20 ↩↩

8. Moody's Assigns Prime-2 Commercial Paper Rating to Vylor Inc. — Moody's Ratings, 2026-09-23 ↩

9. Fitch Assigns First-Time 'BBB+' Long-Term Issuer Default Rating to Vylor Inc. — Fitch Ratings, 2026-08-25 ↩

10. S&P Global Ratings Assigns 'BBB+' Issuer Credit Rating to Vylor Inc. — S&P Global Ratings, 2026-08-22 ↩↩

11. Bayer and Corteva Agriscience Resolve Longstanding Seed Trait Disputes — Reuters, 2026-01-15 ↩↩

12. California Leads 19 States in Challenge to Corteva Chemical Spin-Off Over PFAS Liabilities — Bloomberg Law, 2026-09-18 ↩↩

13. Fourth Circuit Court of Appeals Docket for South Carolina AFFF MDL (In re Aqueous Film-Forming Foams Products Liability Litigation) — U.S. Court of Appeals for the Fourth Circuit, 2026-09-30 ↩

14. Pioneer Hi-Bred International: The Century of Seed Innovation That Built Johnston — Des Moines Register, 2026-04-20 ↩↩↩↩↩

15. Corteva, Inc. Form 10-K for the Fiscal Year Ended December 31, 2025 — SEC EDGAR, 2026-02-06 ↩↩↩↩